Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions
Covid19
Interventions
DRUG

Favipiravir

Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7

DRUG

Nitazoxanide

Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7

OTHER

Nitazoxanide Placebo

Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.

Trial Locations (1)

02290

"Hospital de Infectología Daniel Méndez Hernández del Centro Médico Nacional La Raza", Mexico City

All Listed Sponsors
collaborator

University College, London

OTHER

collaborator

Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV)

UNKNOWN

collaborator

Universidad Autonoma de Guadalajara

UNKNOWN

collaborator

Siegfried Rhein S.A. de C.V.

UNKNOWN

collaborator

Strides Pharma Science Limited

UNKNOWN

collaborator

Hakken Enterprise

UNKNOWN

lead

Coordinación de Investigación en Salud, Mexico

OTHER_GOV

NCT04918927 - Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19 | Biotech Hunter | Biotech Hunter